Capri­cor to re­sume dos­ing in DMD tri­al — but scarce re­sources force com­pa­ny to pause en­roll­ment, cut jobs

Lit­tle Capri­cor $CAPR is do­ing its best to lim­it the dam­age of its big prob­lems. On Wednes­day, the com­pa­ny said it is ex­plor­ing strate­gic al­ter­na­tives for one or more of its prod­ucts and cut­ting 21 jobs to keep fi­nan­cial­ly afloat in­to late 2019, and on the pos­i­tive front said it had re­sumed dos­ing in a DMD tri­al it had vol­un­tar­i­ly halt­ed last De­cem­ber af­ter a pa­tient had a “se­vere al­ler­gic re­ac­tion” dur­ing in­fu­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER